PI3K 抑制剂能否解乳腺癌内分泌治疗耐药的燃眉之急？以 PI3K 抑制剂为基础的联合治疗对于内分泌耐药人群的治疗前景如何？本文中，笔者与您一同来探讨这些问题，旨在为临床诊疗提供思路与启发。

Audrey Gross; Head of Corporate Communications; Aadi Bioscience Inc. Dave Lennon; President, Chief Executive Officer, Principal Executive Officer; Aadi Bioscience In ...

The field of cardio-oncology has expanded over the past 2 decades to address the ever-increasing issues related to cardiovascular disease in patients with cancer and survivors. There is increasing ...

Adding metformin to letrozole and abemaciclib (Verzenio) was tied to deep responses and prolonged progression-free survival ...

Promising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor ...

Metastatic breast cancer is complex, requiring holistic care and ongoing treatment, with varying prognosis depending on ...

Single-cell analysis revealed the molecular triggers that drive stem cells to become cancerous, which may help inform ...

PR+ breast cancer responds well to hormone therapy, underscoring the need for molecular insight and targeted treatment ...

Scientists at Southern University of Science and Technology in Shenzhen, China, have identified a new regulator of the mammalian target of rapamycin (mTOR) pathway associated with the growth of ...

A team led by Prof. Wuran Wei from West China Hospital of Sichuan University and Dr. Dechao Feng from the Division of Surgery and Interventional Science at University College London has systematically ...

mTOR has been shown to have a significant role in the signalling pathway that regulates ... CPRIT funding has advanced scientific and clinical knowledge and provided 7.4 million life-saving cancer ...